Ser339

Site Information
LFAGQHIsksPFEVs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23107460

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , esophageal cancer ( 2 ) , esophageal carcinoma ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , Kyse180 (esophageal) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Tucker M (2010) CST Curation Set: 9227; Year: 2010; Biosample/Treatment: cell line, Kyse180/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275 Curated Info

Tucker M (2010) CST Curation Set: 9227; Year: 2010; Biosample/Treatment: cell line, Kyse180/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info